Peanut Allergy Treatment Market to Reach Valuation of USD 1278.3 Million by 2032 – Advancements in Medical Research & Technology And Rising Awareness about Peanut Allergies Drives the Market

In terms of revenue, the Global Peanut Allergy Treatment Market is expected to reach by 2032, growing at a CAGR (Compound Annual Growth Rate) of 11.6% from 2024 to 2032.

Peanut allergies are a common food allergy affecting children and adults. The market analysis and estimations revolve around various treatment options such as medications, oral immunotherapy, sublingual immunotherapy, and desensitization therapy. According to the FDA, peanut allergy affects around 1 million children in the U.S., and only about 1 out of 5 of these children will outgrow their allergy. Additionally, the increasing awareness and diagnosis of peanut allergies have contributed to the market's growth. As more people become aware of the potential dangers of peanut allergies, there is a higher demand for effective treatments and therapies. This has led to investments in R&D by pharmaceutical companies and healthcare providers to create new and better therapies.

Advancements in technology and increased investment in research and development have also contributed to the market's growth. New diagnostic tools, such as specific IgE blood tests, have made diagnosing peanut allergies easier and more accurate, increasing demand for treatments. Additionally, immunotherapies and biological treatments are two new therapeutic alternatives produced through ongoing research and clinical trials, bolstering the market's expansion. For instance, Syneos Health is currently carrying out clinical trials for a Biological substance known as the Peanut SLIT tablet. This substance is currently in phase 1 of testing, and the trials are expected to be completed by November 2023.

Key Highlights from the Report

• Based on the Drug Class segmentation, the Epinephrine segment dominates the Peanut Allergy Treatment market in 2023 owing to the rising awareness about anaphylactic reactions and the effectiveness of epinephrine in managing allergic reactions.
• Furthermore, based on the segmentation of the Route of Administration, the Injectable segment is predicted to show the most significant growth in the market in 2023 due to the promising results of injectable treatments in clinical trials and the focus on research & development of innovative therapies.
• In addition, based on the Distribution Channel segmentation, the Hospital Pharmacy sector experienced the most potential market growth in 2023 due to the effective distribution of critical drugs and treatments for allergy management in a hospital setting.
• Finally, based on the Region segmentation, North America holds the significant market share within the Peanut Allergy Treatment market in 2023, owing to the government initiatives & regulations and an increase in the prevalence of peanut allergies in this region. 

Market Dynamics

The significant impact of peanut allergies on public health is driving the  demand for market. The National Institutes of Health (NIH) estimates that 3 million Americans, or 1.1% of the total population, suffer from a peanut allergy. An in-depth analysis of prevalence data from the Journal of Allergy and Clinical Immunology sheds light on the unique characteristics of adult peanut allergies in the United States. The data shows that the current self-reported peanut allergy rate is 2.9%, with 1.8% having convincing peanut allergy (PA) and over 17% experiencing the onset of peanut allergy in adulthood. This highlights the complexities of this health issue. It is worth noting that there is a distinction between childhood-onset and adult-onset peanut allergies. 

Among adults with childhood-onset PA, 75.4% reported a physician-diagnosed allergy, compared to 58.9% in the adult-onset category. The data also reveals the importance of epinephrine in managing peanut allergies. Adults with childhood-onset peanut allergies are significantly more likely to have a current epinephrine prescription (56% vs. 44%) and are more prone to use an epinephrine autoinjector (48% vs. 35%). These insights highlight the need for advancements in the Market to address this patient population's diverse needs and complexities.

North America led the Peanut Allergy Treatment market in 2023. Over the past decade, there has been an increase in public awareness campaigns and educational programs aimed at raising awareness about peanut allergies. These initiatives have helped in early diagnosis and treatment of peanut allergies, leading to a greater demand for effective treatment options. In addition, governments in North America have taken significant measures to support research and development in . This include contributing to clinical trials using funds, sponsoring research initiatives, and working with pharmaceutical firms to create novel treatment approaches. This government support has further accelerated the growth of the market.

The Global Peanut Allergy Treatment Market is Segmented as follows

• Drug Class
  • Antihistamines
  • Epinephrine
  • Immunotherapies
  • Other Drug Classes
• Route of Administration
  • Oral
  • Injectable
  • Other Routes of Administration
• Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Other Distribution Channels
• Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

List of the Key Players of the Global Peanut Allergy Treatment Market is

Alladapt Immunotherapeutics Inc. (U.S.), DBV Technologies (France), Aimmune Therapeutics Inc. (U.S.), Aravax Pty Ltd. (Australia), Sanofi (France), Vedanta Biosciences Inc. (U.S.), Regeneron Pharmaceuticals Inc. (U.S.), Teva Pharmaceuticals Industries Ltd. (Israel), Prota Therapeutics (Australia)

The Global Peanut Allergy Treatment Market Scope can be Tabulated as below